501130-49-0

Basic information

• Product Name: 6-Bromoisoquinoline-1,3(2H,4H)-dione
• Synonyms: 6-Bromoisoquinoline-1,3(2H,4H)-dione;6-BroMo-4H-isoquinoline-1,3-dione
• CAS NO: 501130-49-0
• Molecular Formula: C9H6BrNO2
• Molecular Weight: 240.05344
• Product Categories: organic building block
• Mol File: 501130-49-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 442.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.696±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 9.70±0.20(Predicted)
• CAS DataBase Reference: 6-Bromoisoquinoline-1,3(2H,4H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromoisoquinoline-1,3(2H,4H)-dione(501130-49-0)
• EPA Substance Registry System: 6-Bromoisoquinoline-1,3(2H,4H)-dione(501130-49-0)

Safety Data

• Hazardous Substances Data: 501130-49-0(Hazardous Substances Data)

Usage

General Description

6-Bromoisoquinoline-1,3(2H,4H)-dione, also known as 3,6-Dibromoisoquinoline-1,3(2H,4H)-dione, is a chemical compound with the molecular formula C9H4Br2NO2. It is a yellow to brown solid that is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 6-Bromoisoquinoline-1,3(2H,4H)-dione is a versatile building block for the production of various organic compounds due to its reactivity and potential for substitution reactions. It is also used in research and development as a starting material for the synthesis of diverse functionalized isoquinoline derivatives. Additionally, 6-Bromoisoquinoline-1,3(2H,4H)-dione has potential applications in the fields of medicinal chemistry and chemical biology.

Upstream product

• 925672-87-3 C₁₁H₇BrN₂O₂ 
• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 925672-88-4 4-bromo-2-(cyanomethyl)benzonitrile 
• 943749-63-1 4-bromo-2-(carboxymethyl)benzoic acid 
• 57-13-6 urea 
• 698-67-9 p-bromobenzamide 
• 501130-36-5 dithiocarbonic acid S-[2-(4-bromo-benzoylamino)-2-oxo-ethyl] ester O-ethyl ester 

Downstream Products

• 552331-06-3 6-bromo-3-chloro-isoquinoline 
• 552331-05-2 6-bromo-1,3-dichloroisoquinoline 

Relevant articles and documents

Synthesis of medical intermediate disubstituted N-containing heterocycle amine compound

The invention relates to synthesis of a medical intermediate disubstituted N-containing heterocycle amine compound. The synthesis comprises the following steps: reacting 5-bromo-2-carboxy-phenylaceticacid, urea and o-dichlorobenzene as raw materials to obtain 6-bromoisoquinoline-1, 3 (2H,4H)-dione; allowing the 6-bromoisoquinoline-1, 3 (2H,4H)-dione to react with phenyl dichloro sphosphineoxide,adding tetrahydrofuran to precipitate out, adjusting the pH value, and then passing through a column to obtain 1, 3-dichloro-6-bromoisoquinoline; then adding glacial acetic acid, red phosphorus and hydroiodic acid, and after the reaction, determining whether the reaction is complete or not by TLC, subjecting the filtrate and the filter cake to repeated fine treatment to obtain 3-chloro-6-bromoisoquinoline; adding copper sulfate pentahydrate, 6-bromo-3-chloroisoquinoline and a large amount of 15% ammonia water to react in a high-pressure kettle, extracting and passing column for many times according to different requirements to obtain the final product 3-chloro-6-aminoisoquinoline.

Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment

Insulin-like growth factor receptor (IGF-1R) is a growth factor receptor tyrosine kinase that acts as a critical mediator of cell proliferation and survival. This receptor is over-expressed or activated in tumor cells and is emerging as a novel target in cancer therapy. Efforts in our "Hit to Lead" group have generated a novel series of submicromolar IGF-1R inhibitors based on a isoquinolinedione template originating from a Lance enzyme HTS screen. Chemical triage and parallel synthesis incorporating focused library arrays were instrumental in moving these investigations through the Wyeth exploratory medicinal chemistry process. The strategies, synthesis, and SAR behind this interesting kinase scaffold will be described.

An expedient synthesis of homophthalimides

The six-membered heterocyclic subunit of homophthalimides can be obtained by a direct, hitherto unprecedented, radical cyclisation onto an aromatic ring starting from a xanthate precursor.